Shehnaaz Suliman, MD, MPhil, Discusses Targeted Respiratory Therapies on “Close to the Edge”

ReCode Therapeutics CEO shares how she overcame apartheid in her native South Africa to build careers as a physician, investment banker, and biopharma executive


Suliman pivoted to investment banking about two decades ago, earning an MBA at Oxford University, then holding positions at Lehman Brothers and later Petkevich & Partners. A few years later, she embarked on a successful career as a biotech business development executive. At Gilead, Suliman held management roles of increasing responsibility between 2005 and 2010 and played a significant role in expanding the company into new therapeutic areas, notably HIV . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

Previous articleScreening for Druggable RNA Targets Opens Door to Drug Development
Next articleFirst Complete Human Genome, For Real This Time